"The Report Breast Cancer
Therapeutics in Southeast Asia Markets to 2022 - Increasing
Prevalence and Usage of Premium Targeted Therapies to Drive the
Market provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz
Breast cancer is a malignant
neoplasm that begins in the breast tissue. Most breast cancers are
invasive cancers that have grown beyond the ducts or lobules and can
metastasize to other parts of the body through the bloodstream and
the lymphatic system. Broadly, patients can be segmented into two
types: the human epidermal growth factor receptor (HER) 2-negative
segment and the HER2-positive segment. HER2-positive breast cancer is
aggressive and, historically, has had a worse overall survival than
HER2-negative disease, which is considered less aggressive.
In HER2-negative breast cancer, a
number of different factors can influence the choice of therapy that
a patient receives, including the stage of the cancer, the hormonal
receptor status of the cancer (ER-positive or -negative and
PR-positive or -negative) and whether the patient is a BRCA-mutation
carrier. Triple-negative breast cancer (TNBC) is a setting with
incredibly high unmet needs, with no targeted therapy options being
available. Chemotherapy is the mainstay of treatment in this setting.
For HR-positive disease, endocrine therapies are the primary
treatment.
View Report @
http://www.marketresearchreports.biz/analysis/1068037
Survival for HER2-positive breast
cancer patients has increased, due to established disease management
strategies using numerous combinations of chemotherapy along with
targeted therapies such as Herceptin, Tykerb (lapatinib) and Perjeta
(pertuzumab). These newer therapies are expected to significantly
improve survival outcomes in all lines of the disease. The
introduction of Herceptin, the first HER2-targeting agent for
metastatic disease, greatly improved the outcome of patients with
HER2-positive breast cancer, bringing survival rates close to those
of HER2-negative, HR-positive breast cancer.
In most Southeast Asian countries,
the highest unmet need lies in the lack of a defined treatment plan
for the disease, poor affordability, and patients continuing to rely
on the use of chemotherapies in the later lines of treatment. It is
important for drug companies to consider the evolving reimbursement
landscape when determining pricing strategies across the Southeast
Asian markets, because this will significantly impact the uptake of
premium drugs.
Scope
The current Southeast Asia breast
cancer market contains well-established novel targeted products such
as Perjeta and Kadcyla, tyrosine kinase inhibitors such as Tykerb,
and CDK inhibitors such as Ibrance.
- Which drugs are used as the standard treatment in each setting of the disease?
- What are the competitive advantages of the existing novel drugs?
- Do branded therapies show continued growth, and how does their expected uptake influence the market growth over the forecast period?
There are about 1,150 active
pipeline molecules. The pipeline contains a range of molecule types
and molecular targets, including those that are well established in
breast cancer, and novel, first-in-class therapies.
- Which molecular targets appear most frequently in the pipeline?
- There is currently no approved therapy in the TNBC setting. Are there any drugs in the pipeline to improve treatment for TNBC?
- Targets that are not currently represented by marketed products are virtually absent from the late-stage pipeline. Does the early stage pipeline have experimental molecules designed to target novel pathways?
Get Sample Copy Of this Report
@
Analysis of clinical trials since
2006 identified that the failure rates of breast cancer molecules
were highest in Phase II, at 59%, with the overall attrition rate for
breast cancer standing at 85%.
- How do failure rates vary by stage of development, molecule type, and molecular target?
- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
The breast cancer Southeast Asian
market will be valued at $2.7 billion in 2022, growing from $942.3m
in 2015 at a CAGR of 16.2%.
- Despite an array of treatments being available for breast cancer, there is still an unmet need in the Southeast Asian markets related to low uptake of targeted therapies. Will this scenario change during the forecast period?
Market forecasts indicate that
South Korea will continue to be the largest market in Southeast Asia,
due to the emergence of novel therapies and the continued uptake of
branded therapies.
- How will the annual cost of therapy and market size vary between the eight Southeast Asian markets?
- What are the factors that contribute to the increase in ACoT and market size for each of the assessed countries?
- How will branded therapies be affected by upcoming pipeline therapies in each of the assessed countries?
- How will the potential launch of biosimilars influence each country?
- Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?
Various drivers and barriers
will influence the market over the forecast period.
- What barriers limit the uptake of premium-priced therapeutics in the assessed countries?
- What factors are most likely to drive the market in these countries?
Reasons to buy
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the breast cancer market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are also highlighted to allow a competitive understanding of gaps in the market.
- Analyze the breast cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict breast cancer market growth in the eight Southeast Asian markets, with epidemiological and annual cost of therapy forecasts, as well as analysis of the contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals.
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment